Intranasal NIC-hLYS is efficacious in vivo against MERS-CoV. by Ashlee D. Brunaugh (4263472)

“…<p>The efficacy of NIC-hLYS particles was assessed in a lethal MERS-CoV infection model (A). Once daily intranasal administration of NIC-hLYS particles suspended in 0.45% sodium chloride resulted in 43% survival in a lethal MERS-CoV infection (B) and produced a statistically significant decrease in lung viral titer at the highest dose tested (C). …”

Intranasal NIC-hLYS is efficacious in vivo against MERS-CoV. by Ashlee D. Brunaugh (4263472)

“…<p>The efficacy of NIC-hLYS particles was assessed in a lethal SARS-CoV-2 infection model (A). Once daily intranasal administration of NIC-hLYS particles suspended in 0.45% sodium chloride resulted in 30% survival in a lethal SARS-CoV-2 infection (B) and produced a statistically significant decrease in lung viral titers after 10 days of dosing (C). …”

Pre-ART plasma barcode proportion during primary infection. by Brandon F. Keele (7450001)

CsrA modulates the expression of a thiamine pyrophosphate (TPP) riboswitch element. by Tobias Sahr (3756775)

“…<b>B</b>) EMSA with 200nM of biotinylated thi-element (TPP) RNA and purified CsrA: Lane 1: no CsrA, lane 2: 1.0 μM CsrA, lane 3: 2.0 μM CsrA, lane 4: 5.0 μM CsrA, lane 5: 5.0 μM CsrA + 2.0 μM unlabeled RsmZ. …”

Histological abnormalities in E18.5 ATF2 mutant cerebellum and brainstem. by Julien Ackermann (223933)

“…Number of hypoglossal motoneurons (h) is bilaterally decreased in <i>Atf2^−/−</i> embryos while number of dorsal vagal motoneurons (v) appears normal. …”

Characteristics of study subjects. by Bi Xue Patricia Soh (21100364)

“…Upon TID adjustment, the percentage of vegans meeting adequacy for protein and IAA decreased and only approximately 50% of the cohort could meet lysine and leucine requirements. …”

Fig 4 - by Xiu-Qi Chen (13832389)

“…NETs in gastric tissues. Scale label 50 μm. NETs were observed in IgAV model group and decreased in DNase I intervention group but absent in control group. …”

Fig 5 - by Xiu-Qi Chen (13832389)

Ca²⁺ supplementation <i>in vitro</i> increases cell death in polarized human macrophages and favours an M1 phenotype. by Yusuf Cem Eskiocak (10789281)

Effect of BPA on CYP450s expression, and nicotine modulation, in fetal rat brain by Mohammad H., Merii

“…Fetal brains were isolated at gestational days GD14 and GD19, and protein expression was assessed by Western blotting. Results showed a BPA-induced significant decrease in CYP1B1 expression levels at GD14 (p = 0.001), and CYP19A1 (aromatase) expression at both mid- and late-stage development (p < 0.001). …”
Get full text
Get full text
Get full text

Binding analysis of typical ligands for T1rs to T1r2a/T1r3LBD. by Hikaru Ishida (18239420)

De-identified dataset. by Zeshan A. Chisty (18388200)

“…</p><p>Results</p><p>The median age of the 37 participants at enrollment was 70.5 years; 30 (81%) had prior SARS-CoV-2 infection, and 76% received Pfizer-BioNTech and 24% Moderna homologous vaccines. …”

Superhydrophobic Modification of Atomic Layer Deposition Antireflection Aluminum Oxide Film: A Simple Evaporative Coating Technique by Zeyu An (19798137)

EA treatment restored <i>Stat</i>5NKO-induced obese phenotype, improved energy metabolism and cold tolerance in the <i>Stat</i>5NKO obese mice. by Shu-Ping Fu (549948)

“…(E &F) EA treatment decreased <i>Stat</i>5NKO obese mice adipocyte size. …”

Subgroup analysis. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Study outcomes. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Adverse childhood experiences and chronic lung diseases in adulthood: a systematic review and meta-analysis by Samuel Lopes (8411688)

Adverse events ^a. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”